The CD19 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the CD19 gene in the 769-P human cell line. This product provides a heterogeneous pool of cells bearing CD19 gene disruption, retaining the benefits of polyclonal knockout models such as reduced clonal artifacts and representation of multiple editing events. The knockout is generated using a general CRISPR/Cas9-mediated gene disruption strategy, creating a robust loss-of-function system for investigating CD19 biology without reliance on a single clonal isolate.
The parental 769-P cell line was derived from a primary clear cell renal adenocarcinoma and serves as a well-established model in renal carcinoma research. These adherent epithelial cells maintain hallmark characteristics of clear cell renal cell carcinoma, including relevant oncogenic mutations and signaling dependencies. The 769-P line is widely utilized to study tumor cell proliferation, invasion, and drug response, making it a suitable host for exploring gene function in a kidney cancer background. Its non-lymphoid origin offers a distinct cellular context for examining the roles of genes typically associated with hematopoietic lineages.
CD19 is a B-cell lineage-specific surface glycoprotein that functions as a co-receptor for the B-cell antigen receptor (BCR). Upon BCR cross-linking, CD19 is rapidly phosphorylated by Lyn kinase and recruits the PI3K p85 subunit, forming a signaling complex with CD21 (complement receptor 2) and CD81 (TAPA-1). This complex amplifies downstream cascades through activation of Vav, PLC??2, Ras, and ERK, and culminates in NF-??B p65-mediated transcriptional responses. Upstream regulators such as IL-4 and CD21 ligand binding further modulate CD19 activity, positioning it as a central node in B-cell development, activation, and differentiation.
In the context of 769-P renal carcinoma cells, the CD19 knockout model enables exploration of CD19 function in a non-hematopoietic microenvironment. This is particularly relevant for studies assessing the impact of CD19 loss on tumor cell behavior, potential crosstalk with infiltrating immune cells, or off-target effects of CD19-directed immunotherapies, including CAR-T cells and bispecific antibodies. By providing a clean genetic background devoid of CD19 expression, researchers can dissect signaling mechanisms that may be co-opted in renal carcinoma or evaluate the specificity of CD19-based therapeutic tools.
This polyclonal knockout cell population is suitable for a broad range of applications, including B-cell receptor signal transduction studies, validation of CD19 as a therapeutic target, and drug sensitivity screening. Recommended assays for characterizing the CD19 knockout include western blotting for protein expression, RT-qPCR for mRNA levels, flow cytometry for surface marker analysis, co-immunoprecipitation of signaling complexes, phospho-kinase arrays for downstream pathway activation, and cell proliferation assays. These experimental approaches enable comprehensive assessment of CD19-mediated signaling and functional outcomes. For additional technical details and ordering information, please contact Ascent Research.
